These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3420571)

  • 41. [Comprehensive detection of severe, potentially life-threatening drug side effects].
    Schönhöfer PS; Wessely-Stickel B; Schulte-Sasse H; Werner W
    Verh Dtsch Ges Inn Med; 1989; 95():687-90. PubMed ID: 2603504
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 43. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 46. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

  • 47. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
    Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 50. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 51. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 52. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 53. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Notifying patients of adverse drug reactions.
    Pane FJ; Ringer L; Ferguson L; Koshko N
    Am J Hosp Pharm; 1991 Feb; 48(2):236-7. PubMed ID: 2003491
    [No Abstract]   [Full Text] [Related]  

  • 55. Multicenter study of hospital adverse drug reactions.
    Conforti A; Leone R; Moretti U; Sartori M; Velo GP
    Acta Physiol Hung; 1990; 75 Suppl():63-4. PubMed ID: 2196759
    [No Abstract]   [Full Text] [Related]  

  • 56. Epidemiologic assessment of adverse drug effects.
    Stern RS
    Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
    [No Abstract]   [Full Text] [Related]  

  • 57. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 58. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 60. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.